Ethics of Off-Label Marketing of Drugs: Patient Safety Versus Commercial Profits
- 1 January 2025
- book chapter
- Published by Springer Nature
- p. 105-127
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Off-Label Use vs Off-Label MarketingJACC: Basic To Translational Science, 2023
- Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved IndicationsJAMA Internal Medicine, 2022
- Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo FrameworkClinical Pharmacology & Therapeutics, 2021
- Problematic Promotion of Medications by Nurse Ambassadors—Legal and Ethical IssuesJAMA, 2021
- Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance ProgramsJAMA, 2019
- Increasing the Participation of Pregnant Women in Clinical TrialsJAMA, 2018
- Trends and Characteristics of US Medicare Spending on Repository CorticotropinJAMA Internal Medicine, 2017
- Association of Off-label Drug Use and Adverse Drug Events in an Adult PopulationJAMA Internal Medicine, 2016
- Guest Authorship and Ghostwriting in Publications Related to RofecoxibJAMA, 2008
- Off-label Prescribing Among Office-Based PhysiciansArchives of internal medicine (1960), 2006